|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����Ǵ�,Ƥ�� |
|
���� |
| ��������������� | |
|
���� |
|
�Ź��� |
|
��ǧ�� |
| PubMed | |
|
Article by LIU Chun |
|
Article by ZHANG Guo-yi |
|
Article by WANG Qian-qiu |
Ƥ���ͺ���Ǵ���������״
����, �Ź���, ��ǧ��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
Ƥ���ͺ���Ǵ��Ǻ���Ǵ���������Խ����һ��,�������б���ϵͳ�Ժ���Ǵ�,Ŀǰ���̶�������ģʽ���ֲ�������Ƥ�ʼ����ǹ㷺���õ������ֶ�֮һ,�Ը���Ƥ���ͺ���Ǵ�����Ч�������͵������Ƽ�������Ī˾������Ī˾,��Ҫ�������ƶ���Ƥ�ʼ��غͳ���ҩ����Ч��Ƥ���ͺ���Ǵ���������ҩ��������Ч��Ƥ��,��ѡ��Ƥ����ע����Ƥ�ʼ���,�Կ��ٷ��ӿ��������������á�ϸ����ҩ���ɳ���Ȱ���Ҫ���Ƹ�����������Ƥ���ͺ���Ǵ������⼰����Ҳ����Ч����Ƥ���ͺ���Ǵ���Ƥ��
Management of Cutaneous Lupus Erythematosus
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Cutaneous lupus erythematosus is a relatively mild subtype in the spectrum of lupus erythematosus. The management of cutaneous lupus erythematosus is different from that of systemic lupus erythematosus (SLE). Topical therapies are usually useful in the treatment of cutaneous lupus erythematosus. When lesions are not controlled with topical corticosteroids, intralesional corticosteroids are often indicated. Antimalarial, corticosteroid,retinoids are mainstays in systemic therapy, and cytotoxic agents and thalidomide are effective for patients who are resistant to routine therapies. Pulsed dye laser and ultraviolet therapy can be helpful in the treatment of cutaneous lupus erythematosus.
[2] Lampropoulos CE,Sangle S,Harrison P,et al.Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus:a possible alternative.Rheumatology (Oxford),2004,43:1383-1385.
[3] Tlacuilo-Parra A,Guevara-Gutierrez E,Gutierrez-Murillo F,et al.Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.Rheumatology (Oxford),2005,44:1564-1568.
[4] Fabbri P,Cardinali C,Giomi B,et al.Cutaneous lupus erythematosus:diagnosis and management.Am J Clin Dermatol,2003,4:449-465.
[5] Wozniacka A,McCauliffe DP.Optimal use of antimalarials in treating cutaneous lupus erythematosus.Am J Clin Dermatol,2005,6:1-11.
[6] Wallace DJ.Antimalarials-the 'real' advance in lupus.Lupus,2001,10:385-387.
[7] Kuhn A,Richter-Hintz D,Oslislo C,et al.Lupus erythematosus tumidus-a neglected subset of cutaneous Lupus erythematosus:report of 40 cases.Arch Dermatol,2000,136:1033-1041.
[8] McCauliffe DP.Cutaneous lupus erythematosus.Semin Cutan Med Surg,2001,20:14-26.
[9] Al-Mutairi N,Rijhwani M,Nour-Eldin O.Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy.J Dermatol,2005,32:482-486.
[10] Neri R,Mosca M,Bernacchi E,et al.A case of SLE with acute,subacute and chronic cutaneous lesions successfully treated with Dapsone.Lupus,1999,8:240-243.
[11] Wenzel J,Brahler S,Bauer R,et al.Efficacy and safety ofmethotrexate in recalcitrant cutaneous lupus erythematosus:results of a retrospective study in 43 patients.Br J Dermatol,2005,153:157.
[12] Schanz S,Ulmer A,Rassner G,et al.Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil.Br J Dermatol,2002,147:174-178.
[13] Pisoni CN,Obermoser G,Cuadrado MJ,et al.Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities:poor results with mycophenolate mofetil.Clin Exp Rheumatol,2005,23:393-396.
[14] Goodfield M,Davison K,Bowden K.Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE).J Dermatolog Treat,2004,15:46-50.
[15] Housman TS,Jorizzo JL,McCarty MA,et al.Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.Arch Dermatol,2003,139:50-54.
[16] Cuadrado MJ,Karim Y,Sanna G,et al.Thalidomide for the treatment of resistant cutaneous lupus:efficacy and safety of different therapeutic regimens.Am J Med,2005,118:246-250.
[17] Wu JJ,Huang DB,Pang KR,et al.Thalidomide:dermatological indications,mechanisms of action and side-effects.Br J Dermatol,2005,153:254-273.
[18] Briani C,Zara G,Rondinone R,et al.Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.Autoimmunity,2005,38:549-555.
[19] Bastuji-Garin S,Ochonisky S,Bouche P,et al.Incidence and risk factors for thalidomide neuropathy:a prospective study of 135 dermatologic patients.J Invest Dermatol,2002,119:1020-1026.
[20] Baniandres O,Boixeda P,Belmar P,et al.Treatment of lupus erythematosus with pulsed dye laser.Lasers Surg Med,2003,32:327-330.
[21] Millard TP,Hawk JL.Ultraviolet therapy in lupus.Lupus,2001,10:185-187.